TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00333801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational Rehabilitation Program (VRP)
Description: Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
Study: NCT00122109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 sessions Anger Management Therapy.
Description: Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 sessions Anger Management Therapy.
Description: Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
Study: NCT02781584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily
Study: NCT04219787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long BPL LRYGB
Description: LRYGB with an 180 cm BPL and an AL of 80 cm.
Study: NCT02781584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FENO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FENO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FENO
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS
Description: Administered orally two times daily
Study: NCT00557843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
Study: NCT04219787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short BPL LRYGB
Description: The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
Study: NCT03139240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg oral
Description: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg oral
Description: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given in addition to standard of care medications in women undergoing medical abortion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given in addition to standard of care medications in women undergoing medical abortion
Study: NCT03033524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001
Description: Calculated amount of drug will be diluted with normal saline and administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001
Description: Calculated amount of drug will be diluted with normal saline and administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001
Description: Calculated amount of drug will be diluted with normal saline and administered intravenously.
Study: NCT00557843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
Study: NCT02007668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
Study: NCT00084799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193
Study: NCT01660477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: oral
Study: NCT06678958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction of acetabular defect by trabecular metal augment
Description: The augments were used in the flying buttress position
Study: NCT02776527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
Study: NCT05995379

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed.
Study: NCT03658304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
Study: NCT01795235

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline s.c.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline s.c.

Intervention type: DRUG
Group type: OTHER
Intervention: Glucagon
Description: Glucagon s.c.

Intervention type: DRUG
Group type: OTHER
Intervention: Glucagon
Description: Glucagon s.c.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Sugar Pill

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Sugar Pill

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Beta-1 receptor antagonist

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Beta-1 receptor antagonist
Study: NCT02501772

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupressure by ankle band

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure by ankle band
Study: NCT04229160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive mapping (Cardioinsight® system)
Description: Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term cardiac monitoring (LINQ system)
Description: long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation ablation procedure
Description: Atrial Fibrillation ablation procedure is done with standard practice
Study: NCT00476593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
Study: NCT02938013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
Description: antiviral therapy for HCV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL)
Description: antiviral therapy for HCV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL)
Description: antiviral therapy for HCV
Study: NCT03019562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
Study: NCT00856622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i. Fixed combination of latanoprost 0.005% and timolol 0.5%
Description: one drop in the morning and placebo in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5% ophthalmic solution
Description: one drop in the morning and evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: placebo in the morning and latanoprost .005% in the evening
Study: NCT02048696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary prevention and cardiac rehabilitation clinic
Description: Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
Study: NCT03761693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting test
Description: The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting test
Description: The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast.
Study: NCT06033313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negatively Framed text messages
Description: Negatively Framed text messages delivered to participants three times per week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Framed text messages
Description: Positively Framed text messages delivered to participants three times per week for 8 weeks.
Study: NCT03638596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Incentive provided for changing alcohol drinking patterns based on ankle monitor

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
Study: NCT01310361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Benzathin Penicillin G
Description: It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
Study: NCT02431624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTDS
Study: NCT04654936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet
Description: 12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
Study: NCT03916562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of spatiotemporal coordination during walking
Description: A description of the intervention is included in the description of the study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of spatiotemporal coordination during walking
Description: A description of the intervention is included in the description of the study arms.
Study: NCT01204125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR2405550 -BSI-201)
Description: Pharmaceutical form : solution for infusion~Route of administration :Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR2405550 -BSI-201)
Description: Pharmaceutical form : solution for infusion~Route of administration :Intravenous
Study: NCT00997477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foradil Combi (Formoterol-budesonide)
Study: NCT01267916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 6 + 0
Description: Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 10 + 0
Description: Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 16 + 0
Description: Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 6 + 5
Description: Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 10 + 5
Description: Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 16 + 5
Description: Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
Study: NCT06030115

Intervention type: OTHER
Intervention: Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)
Description: Data collected on participants who completed the intensity recovery progression protocol program
Study: NCT00645151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Study: NCT00263627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch pollen allergoid
Description: Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
Study: NCT02540226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical saline
Study: NCT00004195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eniluracil
Description: Will be given to either subject pre-operative and metastatic disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: eniluracil
Description: Will be given to either subject pre-operative and metastatic disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional colon surgery
Description: Only if the subject is amenable to surgical resections

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional colon surgery
Description: Only if the subject is amenable to surgical resections
Study: NCT02015585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interocclusal appliance
Description: Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relining of the complete dentures
Description: Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete denture rehabilitation
Description: All patients will be rehabilitated with new complete dentures in the study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete denture rehabilitation
Description: All patients will be rehabilitated with new complete dentures in the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete denture rehabilitation
Description: All patients will be rehabilitated with new complete dentures in the study